2026
conference-abstract
OpenAlex
Shira Gabizon Peretz, Noam Savion Gaiger, Jacqueline Mann, Harriet M. Kluger
2660 Background: Immune checkpoint inhibitor–induced hepatitis (ICI-hepatitis) is a clinically significant immune-related adverse event (irAE) that may require treatment interruption and immunosuppressive therapy. Predictors of susceptibility to irAEs remain poorly defined. NLRC5 is a key regulator of MHC class I antigen presentation …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Noam Savion Gaiger, Michael E. Hurwitz, Navid Hafez, Harriet M. Kluger et autres
Immune checkpoint inhibitor-induced diabetes is a potentially severe and life-threatening complication of immune checkpoint inhibitor therapy in patients with advanced malignancies. It is typically an irreversible complication due to the complete destruction of pancreatic beta cells that requires ongoing insulin treatment, and …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-paper
OpenAlex
David G. Su, Noam Savion Gaiger, David A. Schoenfeld, Mingze Dong et autres
Background Melanoma brain metastases (MBM) affect approximately 60% of patients with metastatic melanoma and exhibit distinct molecular and immune features compared to extracranial metastases (ECM). 1 2 Prior studies have demonstrated a unique immune microenvironment in MBM, including increased CD8+ T-cell infiltration …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Oscar Perales, Noam Savion Gaiger, Stephanie Elzer Schwartz, Yael Derdikman Ofir et autres
Background Growth and Differentiation Factor 15 (GDF-15) is a secreted cytokine in the TGF-beta superfamily that is highly expressed in the placenta during pregnancy and in certain solid tumors. In cancer, it is thought to help mediate immune escape and possibly resistance …
us
(code pays fourni par la source)
2025
article
OpenAlex
David G. Su, Irvin Yi, Noam Savion Gaiger, David A. Schoenfeld et autres
2025
conference-abstract
OpenAlex
Michael E. Hurwitz, Bryden Considine, Nitzan Hasson, Noam Savion Gaiger et autres
476 Background: Brain metastasis (BM) is an adverse prognostic indicator and associated with poor survival for patients with metastatic renal cell carcinoma (mRCC). Although immune checkpoint inhibitor (ICI) therapy has significantly improved survival in patients with metastatic renal cell carcinoma, the prognostic …
us
(code pays fourni par la source)